E. Gerald Corrigan, Ph.D. Endowed Chair in Alzheimer’s Therapeutic Sciences
Managing Director of the MGH Interdisciplinary Brain Center
Professor of Neurology, Harvard Medical School

After receiving his M.D. from Boston University, Dr. Arnold completed residency training in Psychiatry at the New York State Psychiatric Institute/Columbia Presbyterian Medical Center in New York, and then residency training in Neurology at the University of Iowa Hospitals and Clinics in Iowa City. He also completed fellowship training in Behavioral Neurology / Cognitive Neuroscience and was a post-doctoral associate in Neuroanatomy in Iowa. Dr. Arnold is board certified in both Neurology and Psychiatry. After his training, Dr. Arnold joined the faculty at the University of Pennsylvania where he was Professor of Psychiatry and Neurology until his move to MGH in 2015. At Penn, Dr. Arnold was Director of the Penn Memory Center, Associate Director of the Institute on Aging, Director of the Geriatric Psychiatry Section, and Director of the Cellular and Molecular Neuropathology Laboratory in Psychiatry.

Among Dr. Arnold’s early scientific accomplishments in the field of Alzheimer’s disease (AD), he was the among the first to comprehensively map the distribution of plaques and tangles throughout the brain, revealing discordance between these two defining lesions of the disease. Subsequent work highlighted the especially strong associations that tau tangles have with the clinical syndrome of dementia. Other noteworthy contributions include the description of neuronal insulin resistance as a feature of AD and the characterization of how some people are resistant or resilient to AD, maintaining near normal memory and thinking, despite the build-up of plaque and tangle pathology in their brains.

Dr. Arnold has authored over 425 publications, with an h-index of 116 and over 45,000 citations (Google Scholar). He has received continuous NIH funding as a principal investigator since 1991and served on numerous editorial, NIH and foundation scientific review committees, as well as industry and community non-profit boards and committees.

Staff Psychiatrist in the Ammon-Pinizzotto Center for Women’s Mental Health at Massachusetts General Hospital
Instructor in Psychiatry at Harvard Medical School

Dr. Baker is an international expert and double board-certified child, adult, and perinatal psychiatrist. She specializes in women’s mental health across the lifespan with a focus on ADHD, adolescent mood and anxiety disorders, and reproductive psychiatry. She is a passionate educator on topics of mental health, with a focus on families. Dr. Baker is an instructor in Psychiatry at Harvard Medical School and is a staff psychiatrist in the Ammon-Pinizzotto Center for Women’s Mental Health at MGH.

Dr. Baker has her MD from the University of Virginia and completed her residency in general psychiatry at Columbia University, serving as Chief Resident. Dr. Baker trained in child and adolescent psychiatry at the combined program of Columbia and Cornell Universities.

Chief, Division of Neuropsychiatry
Director, Transcranial Magnetic Stimulation (TMS) Clinical Service
Director, Laboratory for Neuropsychiatry & Neuromodulation, Massachusetts General Hospital
Associate Professor of Psychiatry, Harvard Medical School

Talk title: “Neurotechnology and novel treatments for Alzheimer’s disease”

Dr. Camprodon is Chief of the Division of Neuropsychiatry and Director of the Laboratory for Neuropsychiatry and Neuromodulation at Massachusetts General Hospital, and Associate Professor of Psychiatry at Harvard Medical School.

Clinically, he is the founding Director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee and an attending physician in the Departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in psychiatry and behavioral neurology-neuropsychiatry.

Dr. Camprodon’s research focuses on Neuropsychiatry and Neuromodulation. Methodologically, he uses multimodal combinations of brain stimulation and neuroimaging/neurophysiology to investigate neural circuitry and plasticity in a translational manner. He uses a wide range of noninvasive and invasive neuromodulation techniques including transcranial current stimulation (tCS, e.g. tDCS/tACS), transcranial magnetic stimulation, transcranial photobiomodulation, electroconvulsive therapy and deep brain stimulation. He also uses multimodal functional and structural MRI, EEG and innovative simultaneous combinations of TMS and tDCS/tACS with neuroimaging and neurophysiology. Projects in his laboratory address (1) circuit level neuropsychiatric pathophysiology (with an emphasis on transdiagnostic processes and the role of plasticity) and (3) the translational development of tools to support clinical care and decision-making (e.g. biomarkers and treatment development).

Assistant Psychiatrist in the Department of Psychiatry
Associate Professor at Harvard Medical School

Dr. Jennifer R. Gatchel obtained her MD/PhD from Baylor College of Medicine working with Dr. Huda Y. Zoghbi studying molecular mechanisms of neurodegeneration. She graduated Alpha Omega Alpha from her medical school class, and received the Hilde Bruch Award for highest honors in Psychiatry. She was subsequently a Chief Resident in Psychopharmacology during her Psychiatry residency training in the Massachusetts General Hospital/McLean Hospital Program. She went on to complete the Harvard Medical School (HMS) Geriatric Psychiatry Clinical Fellowship, and is currently an Assistant Professor of Psychiatry at HMS and an Assistant Psychiatrist in the Department of Psychiatry at Massachusetts General Hospital and in the Division of Geriatric Psychiatry at McLean Hospital.

Dr. Gatchel’s research is focused on understanding the relationships among Alzheimer’s Disease (AD)-associated proteins amyloid and tau, neuropsychiatric symptoms, and cognitive decline in the preclinical and prodromal stages of AD and related dementias. She is utilizing a combination of neuroimaging and detailed clinical and neuropsychological assessments, towards developing better prevention and treatment strategies for individuals at risk for AD, including those with life-long depression. Dr. Gatchel is the recipient of the HMS Department of Psychiatry Dupont Warren Fellowship and Livingston Award, the BrightFocus Foundation Research Fellowship, and the Alzheimer’s AssociationClinical Fellowship. She received the 2016 New Investigator award in Neuropsychiatric Symptoms in Neurodegenerative Diseases from the Alzheimer’sAssociation, and the 2017 Outstanding Emerging Research Scientist Award from the Bright Focus Foundation, and has been recognized as the recipient of leadership awards by the American Association of Geriatric Psychiatry and the American Psychiatric Association (APA). Her clinical research has been supported by the NIH, Massachusetts General Hospital, the Alzheimer’s Association, and the Department of Veterans Affairs.

In her clinical role, Dr. Gatchel sees older adult patients with mood and cognitive disorders and utilizes
transcranial magnetic stimulation to treat depression. She is passionate about advocating for patients with dementia and their families, promoting healthy brain aging and positive mental health and training the next generation of geriatric psychiatrists and clinician-researchers as the Director of the Psychiatry Research Track Program.

Director of the Dauten Family Center for Bipolar Treatment Innovation
Associate Director, Depression Clinical and Research Program
Co-Director, Center for Clinical Research Education
Associate Professor of Psychiatry at Harvard Medical School

Andrew A. Nierenberg, MD is the Director of the Dauten Family Center for Bipolar Treatment Innovation Massachusetts General Hospital and Professor of Psychiatry, Harvard Medical School.

In addition to directing the Dauten Center, Dr. Nierenberg is the co-director of Mass General’s Center for Clinical Research Education and associate director of the Depression Clinical and Research Program. He also holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Mass General.

Dr. Nierenberg graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. After completing his residency in psychiatry at New York University/Bellevue Hospital, he studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, MA and then at Massachusetts General Hospital. He is also an Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong, Australia, and an Honorary Skou Professor at Aarhus University in Denmark.

Dr. Nierenberg focuses on clinical trials for bipolar disorder and depression, with over 590 published papers and a Google Scholar h-index of 125. He has been listed among The Best Doctors or Top Doctors in America for the treatment of mood and anxiety disorders yearly since 1994. He has been honored with the International Society for Bipolar Disorders Mogens Schou Award for Research and the Brain and Behavior Research Foundation’s Colvin Prize. Dr. Nierenberg is currently the PI of the Sequential Multiple Assignment of Treatment study for bipolar depression (SMART-BD) and the Bipolar Disorder Learning Health Network.

Director of Geriatric Psychiatry at the MGH Psychiatry Center for Racial Equity and Justice
Associate Professor of Epidemiology at Harvard Medical School
Associate Professor of Psychiatry at Harvard Medical School

Dr. Okereke is Terry and Jean de Gunzburg MGH Research Scholar 2021-2026, Associate Professor of Psychiatry at Harvard Medical School, and Associate Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. She is Director of Geriatric Psychiatry and Director of the MGH Psychiatry Center for Racial Equity and Justice in the Department of Psychiatry at Massachusetts General Hospital. For the past 15 years, she has been an NIH-funded investigator focusing on modifiable risk factors and prevention of adverse mental aging, including late-life depression, cognitive decline, and dementia, and reduction of health disparities in aging. She has led work that has appeared in such journals as JAMA, JAMA network journals, Annals of Neurology, Journal of Clinical Psychiatry, and the American Journal of Geriatric Psychiatry. She has published over 150 peer-reviewed papers.

Psychiatrist-in-Chief, Emeritus
Director, Center for Neuroscience of Psychedelics
Stanley Cobb Professor of Psychiatry, Harvard Medical School

Until 2019 and for 20 years, Dr. Rosenbaum, Stanley Cobb Professor of Psychiatry at Harvard Medical School, chaired a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019 and for 20 of the prior 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending. At MGH, the nation’s largest hospital based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research. 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was 2016 recipient of the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty for Harvard Medical School. Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee. Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as Chair of the Scientific Council, President and Board member of the American Foundation for Suicide Prevention. He served a 6 year term as Trustee of the Massachusetts General Hospital, 3 years as Trustee of the Partners Healthcare System, and now co-Chair of Development at MGH. Co-author of more than 400 original articles and reviews, and editor of 20 books, he led longitudinal studies of children at risk for anxiety disorders and depression, examining behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders. He currently is directing the MGH Center for Neuroscience of Psychedelics (CNP), to understand how psychedelics change the brain and to explore novel mechanisms for treatment of psychiatric disorders. He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders (www.psythx.com), co-founded Sensorium Therapeutics (www.sensorium.bio), to explore plant derived molecules as leads for novel psychiatric therapeutics, and co-founded Entheos Labs, Inc. to bioengineer novel psychedelic botanicals to deliver a new generation of psychedelic-derived therapeutic molecules. He graduated in 1969 from Yale College and 1973 from Yale Medical School and trained in Psychiatry at Massachusetts General Hospital, Harvard Medical School.

Associate Director of the Dauten Family Center for Bipolar Treatment Innovation
Associate Professor at Harvard Medical School

Dr. Louisa Sylvia is a staff psychologist and associate director at Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, director of the Office for Women’s Careers at Massachusetts General, and an associate professor at Harvard Medical School. Dr. Sylvia’s major research interests are developing resilience and wellness programs for individuals with mood disorders. She has received funding to develop in-person, therapist administered lifestyle and sleep interventions for individuals with serious mental illness as well as online, self-directed programs to increase physical activity and overall wellness.

Dr. Sylvia has published over 150 peer-reviewed manuscripts in her area of specialization, co-authored a workbook for Bipolar II Disorder, authored the Complete Wellness Workbook for Bipolar Disorder as well as presented her work at numerous local, national and international conferences. Specifically, she has developed six in-person, psychosocial-based treatments for individuals with depression and four, online psychosocial interventions for stress as well as developed and launched a new stepped-care, team-based treatment approach for bipolar disorder.

Dr. Sylvia is also a clinician who treats patients with mood and anxiety disorders as well as a prominent educator and mentor in her field. She has spoken nationally on the importance of role models and mentors for female faculty and currently oversees faculty development for women at Massachusetts General Hospital.

Dr. Sylvia received her Bachelor of Arts degree with honors from Wesleyan University in Middletown, CT. She received her doctoral degree in Clinical Psychology at Temple University in Philadelphia, PA and completed her psychology internship at McLean Hospital in Belmont, MA. Dr. Sylvia is a member of the International Society of Bipolar Disorders, Society of Research and Psychopathology, Association of Behavioral and Cognitive Therapies and World Congress of Behavioral and Cognitive Therapy.

Director, Pediatric Bipolar Disorder Clinical and Research Program in Pediatric Psychopharmacology,
Massachusetts General Hospital
Director, Child and Adolescent Psychiatry Outpatient Service, Massachusetts General Hospital
Quality and Safety, Chair, Department of Psychiatry, Massachusetts General Hospital
Associate Professor of Psychiatry, Harvard Medical School
Joseph Biederman Chair in Pediatric Psychopharmacology

Dr. Janet Wozniak received her undergraduate degree from Harvard College where she graduated magna cum laude. During her medical school training at Cornell University Medical College, she earned a SmithKline Beckman Medical Perspectives Award for Outstanding Medical Students. Dr. Wozniak completed her adult and child psychiatry training at Massachusetts General Hospital (MGH). She has since received an Eli Lilly Pilot Research Award, the Elaine Schlosser Lewis Award and Claflin Distinguished Scholar Award. At MGH, she is the director of the Pediatric Bipolar Disorder Clinical and Research Program and the director of the Child and Adolescent Psychiatry Outpatient Service. She is also the Quality and Safety Chair for the Department of Psychiatry. She has received research funding from the National Institute of Mental Health, the Stanley Foundation, the National Alliance for Research in Schizophrenia and Depression, and the Heinz C. Prechter Fund for Manic Depression.

Dr. Wozniak’s research focuses on the characteristics, longitudinal course and treatment of pediatric bipolar disorder. She has addressed the frequent occurrence of pediatric bipolar disorder and its atypical presentation and documented the high rates of comorbidity of pediatric bipolar disorder with other conditions such as attention deficit/hyperactivity disorder, conduct disorder, anxiety disorders and autism, as well as the frequency of occurrence of these disorders within families. Dr. Wozniak has completed one of the few longitudinal course studies of pediatric bipolar disorder, documenting high rates of persistence and the largest family study of the disorder.